(a) TFPI-2 methylation level by qMSP | ||||||
---|---|---|---|---|---|---|
 | n | (%) | Mean | SD | Median | IQR |
Gender | Â | Â | Â | Â | Â | Â |
 Male | 110 | (100) | 13.64 | 13.05 | 8.94 | 21.06 |
Pathological Stage | Â | Â | Â | Â | Â | Â |
 Normal | 24 | (21.8) | 4.45 | 7.51 | 1.79 | 1.62 |
 I | 20 | (18.2) | 16.23 | 12.97 | 13.87 | 16.71 |
 II | 12 | (10.9) | 12.96 | 12.46 | 6.96 | 23.95 |
 III | 25 | (22.7) | 17.19 | 13.62 | 16.86 | 23.15 |
 IV | 29 | (26.4) | 16.67 | 13.60 | 16.64 | 19.61 |
Cancer Site | Â | Â | Â | Â | Â | Â |
 Buccal | 36 | (41.9) | 17.05 | 12.46 | 15.95 | 18.90 |
 Tongue | 50 | (58.1) | 15.59 | 13.71 | 11.66 | 22.63 |
(b) TFPI-2 methylation level by pyrosequencing | ||||||
 | n | (%) | Mean | SD | Median | IQR |
Gender | Â | Â | Â | Â | Â | Â |
 Male | 60 | (100) | 18.80 | 14.99 | 15.58 | 23.79 |
Pathological Stage | Â | Â | Â | Â | Â | Â |
 Normal | 11 | (18.3) | 4.43 | 1.91 | 3.82 | 2.94 |
 I | 15 | (25.0) | 20.35 | 12.19 | 18.26 | 23.14 |
 II | 12 | (20.0) | 16.21 | 9.48 | 12.17 | 12.97 |
 III | 14 | (23.3) | 21.63 | 16.08 | 21.03 | 28.34 |
 IV | 8 | (13.3) | 34.63 | 18.06 | 33.10 | 23.50 |
Cancer Site | Â | Â | Â | Â | Â | Â |
 Buccal | 19 | (38.8) | 29.70 | 14.41 | 28.12 | 16.07 |
 Tongue | 30 | (61.2) | 17.18 | 12.96 | 13.86 | 20.82 |